Category - Feature

Feature

Kintara Therapeutics readies two late-stage cancer drug candidates

Kintara Therapeutics (NASDAQ:KTRA), fresh off a merger and $25-million private placement, is moving into a global registration trial in newly-diagnosed and recurrent glioblastoma multiforme (GBM), a deadly brain cancer...

November 17, 2020

Feature

Hepion Pharmaceuticals employing artificial intelligence to tackle NASH

After close to three decades developing its artificial intelligence platform, Hepion Pharmaceuticals (NASDAQ:HEPA) is deploying its AI-POWR machine learning platform in its clinical program to tackle non-alcoholic...

November 10, 2020

Feature

Micron developing microneedle technology for self-administration of vaccines and therapeutics

Closely-held Micron Biomedical is developing a dissolvable microneedle-based technology that could enable self-administration of vaccines and therapeutics.

November 3, 2020

Feature

9 Meters Biopharma targeting rare and unmet needs in GI disorders

By Leonard Zehr 9 Meters Biopharma (NASDAQ: NMTR) expects to report clinical trial data readouts in 2021 from two gastrointestinal disorders: short bowel syndrome, an underserved and debilitating rare disease, and...

October 27, 2020

Feature

Novamind building infrastructure for regulated psychedelic industry

Closely-held Novamind is building the infrastructure required to facilitate safe, legal and medically-supervised psychedelic-assisted therapy. “We saw an opportunity to build a sustainable business in a market that’s...

October 20, 2020

Feature

Lantern Pharma applying AI to discover and develop cancer therapeutics

Lantern Pharma (NASDAQ:LTRN) is using its RADR AI platform to identify abandoned drug candidates and develop new drugs that may prove effective in treating certain cancers.

October 13, 2020

Feature

Monopar Therapeutics readies two key clinical trials in fourth quarter

Monopar Therapeutics (NASDAQ:MNPR), which focuses on developing cancer therapies and treatments for cancer-related adverse events, is on track for two important clinical trials with its lead drug candidates, Validive...

October 6, 2020

Feature

aTyr Pharma gearing for data readouts in COVID-19, interstitial lung disease

aTyr Pharma (NASDAQ:LIFE) expects to report before the end of 2020 results of a Phase 2 study with its ATYR1923 drug candidate in COVID-19-related severe respiratory complications. It also has a data readout planned in...

September 29, 2020

Feature

Trendlines’ PregnanTech developing Lioness device to prevent preterm birth

Closely-held PregnanTech is completing a clinical safety study with its Lioness device to prevent preterm birth in non-pregnant women about to undergo a hysterectomy as a steppingstone to a larger proof-of-concept study...

September 22, 2020

Feature

BioCardia developing autologous and allogenic cardiovascular cell therapies

BioCardia (NASDAQ:BCDA) is developing two late-stage clinical autologous cell therapies, known as CardiAMP, for ischemic heart failure and chronic myocardial ischemia, a neurokinin 1 receptor positive (NK1R+) allogenic...

September 15, 2020

Category - Feature

Kintara Therapeutics readies two late-stage cancer drug candidates

Hepion Pharmaceuticals employing artificial intelligence to tackle NASH

Micron developing microneedle technology for self-administration of vaccines and therapeutics

9 Meters Biopharma targeting rare and unmet needs in GI disorders

Novamind building infrastructure for regulated psychedelic industry

Lantern Pharma applying AI to discover and develop cancer therapeutics

Monopar Therapeutics readies two key clinical trials in fourth quarter

aTyr Pharma gearing for data readouts in COVID-19, interstitial lung disease

Trendlines’ PregnanTech developing Lioness device to prevent preterm birth

BioCardia developing autologous and allogenic cardiovascular cell therapies

General

More